Rosiglitazone (Avandia) stays on the market, with stronger warnings
by Emily P. Walker
An advisory panel voted 20-12 to recommend that the FDA allow rosiglitazone (Avandia) to stay on the market, but most panelists want to see the controversial diabetes drug carry tougher warnings on its label.
Wednesday’s vote marks the second time an FDA advisory panel has essentially endorsed rosiglitazone. In 2007, a panel voted that while the drug appears to …
Rosiglitazone (Avandia) stays on the market, with stronger warnings
















